Extended-spectrum beta-lactamase (ESBL) testing represents a critical frontline defense in the ongoing battle against antimicrobial resistance. These enzymes, produced primarily by Enterobacteriaceae like Escherichia coli and Klebsiella pneumoniae, render standard penicillins and cephalosporins ineffective, complicating the treatment of serious urinary tract, bloodstream, and abdominal infections. Accurate and rapid detection of ESBL-producing organisms is therefore essential for guiding appropriate antibiotic therapy, implementing infection control measures, and combating the global threat of drug-resistant pathogens.
Understanding ESBL Enzymes and Clinical Significance
ESBLs are enzymes that confer resistance to hydrolysis by most penicillins, first-, second-, and third-generation cephalosporins, and aztreonam. While inhibitors like clavulanic acid, sulbactam, and tazobactam can restore the activity of beta-lactam antibiotics against many ESBLs, the emergence of carbapenemases threatens the last line of defense. The clinical impact of ESBL-producing Enterobacteriaceae is substantial, often associated with increased mortality, prolonged hospital stays, higher healthcare costs, and a greater risk of treatment failure compared to infections caused by susceptible strains. This underscores the non-negotiable need for precise laboratory identification to inform targeted therapeutic decisions.
Common Screening and Confirmatory Methods
Laboratories employ a tiered approach to ESBL detection, beginning with phenotypic screening followed by confirmatory testing. Initial screening often involves disk diffusion or broth microdilution to detect reduced susceptibility to key agents like ceftazidime, cefotaxime, and aztreonam. Isolates demonstrating resistance are subjected to confirmatory tests, with the Clinical and Laboratory Standards Institute (CLSI) recommending the double-disk synergy test (DDST) and the more reliable confirmatory tests such as the cloxacillin-enhanced broth microdilution or the Etest ESBL. These methods are designed to detect the in vitro synergy between a beta-lactam antibiotic and a beta-lactamase inhibitor, providing a definitive indication of ESBL production.
Key Disk Diffusion and Broth Microdilution Thresholds
Interpreting susceptibility results for ESBL screening requires adherence to standardized breakpoints established by CLSI and European Committee on Antimicrobial Susceptibility Testing (EUCAST). For example, specific zone diameter sizes for disks like ceftazidime, cefotaxime, amoxicillin-clavulanate, and ceftriaxone determine whether an isolate is reported as resistant, intermediate, or susceptible. Similarly, minimum inhibitory concentration (MIC) breakpoints in broth microdilution assays provide quantitative thresholds. Understanding these critical values is fundamental for microbiologists to accurately flag potential ESBL producers and initiate appropriate confirmatory workflows, ensuring reliable reporting.
Antibiotic | Key Screening Disk / MIC Breakpoint | Purpose
Ceftazidime | 22 mm (zone) or MIC ≥ 2 µg/mL | Primary indicator of resistance
Cefotaxime | 25 mm (zone) or MIC ≥ 1 µg/mL | Primary indicator of resistance
Amoxicillin-Clavulanate | ≥ 5 mm zone increase vs. cephalosporin or MIC ≤ 1 µg/mL | Confirmatory indicator of inhibitor synergy
